Hengrui Pharmaceutical’s revenue and net profit have doubled for the first time, spending 6.2 billion in innovative drugs a year, and 500,000 shareholders are waiting for the opportunity to buy the bottom – yqqlm

Key Data Concepts:   

? These are the company names, stock quotes, topics, and entities related to this data.

000925 300568 300713 ADD Industry Jiangsu Hengrui Medicine Shenzhen Senior Technology Material Shenzhenrease Technology Unittec Avalanche Accounting, Audit Earnings Layoffs, Downsizing Management Strategy, Marketing Annual, Special Corporate Meeting Annual Report Board Of Directors Research, Development Health, Beauty Product Pharmaceutical Financial, Business Service Insurance Credit, Debt Prices Market, Exchange Water Epidemic Hospital Medicine Health Insurance Economy, Business, Finance Environment Health

Full Data

?
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on the Chinese Stock Markets

Join Now!

Need this critical market data?

Access thousands of market events, data points, and news articles!

Already have an account?
Login

Home » News » Hengrui Pharmaceutical’s revenue and net profit have doubled for the first time, spending 6.2 billion in innovative drugs a year, and 500,000 shareholders are waiting for the opportunity to buy the bottom – yqqlm